[HTML][HTML] Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate cancer and …, 2018 - nature.com
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
J White, BV Shenoy, RF Tutrone… - Prostate cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4-10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
the 4-10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
[HTML][HTML] Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate Cancer and …, 2018 - ncbi.nlm.nih.gov
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
[PDF][PDF] Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate Cancer and …, 2017 - academia.edu
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
[HTML][HTML] Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate Cancer and …, 2018 - nature.com
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting.
J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate Cancer and …, 2017 - europepmc.org
BACKGROUND: Deciding when to biopsy a man with non-suspicious DRE findings and
tPSA in the 4-10 ng/ml range can be challenging, because two-thirds of such biopsies are …
tPSA in the 4-10 ng/ml range can be challenging, because two-thirds of such biopsies are …
[PDF][PDF] Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
J White, BV Shenoy, RF Tutrone, LI Karsh… - Prostate Cancer and …, 2017 - academia.edu
Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …